PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 901–1,000 of 1,000
Mohamed, S. F., Elnaggar, D. H., Abd-Elghaffar, H. S., Elsayed, M. A., Amr, A. E. E., Abou‐Amra, E. S., & Abd‐Elshafy, D. N. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140246 · Cited by 11
Li, N., Sun, Y.-J., Huang, L.-Y., Li, R.-R., Zhang, J.-S., Qiu, A.-H., Wang, J., & Yang, L. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101161 · Cited by 15
Advances in mechanisms of resistance to aromatase inhibitors
Chumsri, S., Schech, A. J., Chakkabat, C., Sabnis, G. J., & Brodie, A. M. H. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.882233 · Cited by 14
Schiff, R., & Jeselsohn, R. M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1084 · Cited by 12
Cyclin-Dependent Kinases As Potential Targets for Colorectal Cancer: Past, Present and Future
Manohar, S. M. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0064 · Cited by 11
Vanhevel, J., Verlinden, L., Loopmans, S., Doms, S., Janssens, I., Bevers, S., Stegen, S., Wildiers, H. P. M. W., & Verstuyf, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.886238 · Cited by 14
Rugo, H. S., Im, S., Joy, A. A., Shparyk, Y. V., Walshe, J. M., Sleckman, B. G., Loi, S., Theall, K. P., Kim, S., Huang, X., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.11.005 · Cited by 16
Chlebowski, R. T. (2013) · Clinical Investigation · doi:10.4155/cli.13.123 · Cited by 12
Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance
Radhi, S. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.009 · Cited by 11
Desai, K., Aiyappa‐Maudsley, R., Prabhu, J. S., Nair, M. G., Lawrence, P. V., Korlimarla, A., Anupama, C. E., Alexander, A., Kaluve, R., Manjunath, S., et al. (2017) · Tumor Biology · doi:10.1177/1010428317695028 · Cited by 12
El-Hashash, M. A. A., El‐Bordany, E. A. A., Marzouk, M. I., El‐Naggar, A. M., Nawar, T. M. S., & El-Sayed, W. M. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180510112614 · Cited by 11
The ING1a model of rapid cell senescence
Bertschmann, J., Thalappilly, S., & Riabowol, K. T. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.06.004 · Cited by 14
Preclinical discovery and development of abemaciclib used to treat breast cancer
Wright, M. D., & Abraham, J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1853097 · Cited by 12
Trapé, A. P., Liu, S., Cortés, A., Ueno, N. T., & Gonzalez-Angulo, A. M. (2016) · Journal of Cancer · doi:10.7150/jca.14441 · Cited by 12
House, N. C. M., Chen, M. M., Khazaei, S., Brown, V. E., Ramsden, P., Peng, D. H., Moore, S., Yuan, L., Wu, R., Wang, F., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00851-7 · Cited by 12
Arndt, C., Tunger, A., Wehner, R., Rothe, R., Kourtellari, E., Luttosch, S., Hannemann, K., Koristka, S., Loureiro, L. R., Feldmann, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.970457 · Cited by 12
Cardiovascular complications of ribociclib in breast cancer patients
Fiste, O., Mavrothalassitis, E., Apostolidou, K., Trika, C. O., Liontos, M., Koutsoukos, K., Kaparelou, M., Dimitrakakis, C., Gavriatopoulou, M., Dimopoulos, M. A., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104296 · Cited by 11
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment
Wu, X., & Xiong, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111407 · Cited by 15
Verhees, F., Demers, I., Legemaate, D., Jacobs, R., Hoeben, A., Kremer, B., & Speel, E. M. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5719 · Cited by 11
Broege, A., Rossetti, S., Sen, A., Forest, A. D. L., Davis, L., Seibel, M. I., Menon, A. S., Stokke, S., Macaulay, A., Molden, J. S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125844 · Cited by 12
Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity
Timpe, L. C., & Wong, T. Y. Y. J. (2015) · Journal of Proteomics & Bioinformatics · doi:10.4172/jpb.1000370 · Cited by 10
Johnston, S. R. D., & Schiavon, G. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e28 · Cited by 10
Belcastro, V., Poussin, C., Gebel, S., Mathis, C., Schlage, W. K., Lichtner, R. B., Quadt‐Humme, S., Wagner, S., Hoeng, J., & Peitsch, M. C. (2013) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s12167 · Cited by 11
Breast Cancer Update 2014 – Focus on the Patient and the Tumour
Maass, N., Schütz, F., Fasching, P. A., Fehm, T. N., Janni, W., Kümmel, S., Kolberg, H., Lüftner, D., Wallwiener, M., & Lux, M. P. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1545704 · Cited by 9
Naqvi, M. F., Vo, H. H., Vining, D. J., & Tsimberidou, A. M. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211001538 · Cited by 10
Zhao, J. J., Fong, K. Y., Chan, Y. H., Tey, J. C. S., Dawood, S. S., Lee, S. C., Finn, R. S., Sundar, R., & Lim, J. S. J. (2023) · Cancers · doi:10.3390/cancers15184558 · Cited by 14
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas, S. L., Darb‐Esfahani, S., von Minckwitz, G., Huober, J., Weber, K. E., Marmé, F., Furlanetto, J., Schem, C., Pfitzner, B. M., Lederer, B., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4581-1 · Cited by 11
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200715 · Cited by 11
Warth, B., Palermo, A., Rattray, N. J. W., Lee, N. V., Zhu, Z., Hoang, L. T., Cai, Y. A., Mazurek, A., Dann, S. G., VanArsdale, T. L., et al. (2019) · Metabolites · doi:10.3390/metabo9010007 · Cited by 12
Zhang, H., Ramsey, A., Xiao, Y., Karki, U., Xie, J. Y., Xu, J., Kelly, T. J., Ono, S., & Zhou, G.-L. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-19 · Cited by 11
Xu, Z., Zhang, H., Wei, D., Xie, L., & Xu, C. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.11.46 · Cited by 9
Magi, S., Ki, S., Ukai, M., Domínguez‐Hüttinger, E., Naito, A. T., Suzuki, Y., & Okada, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-97887-z · Cited by 9
Patient Case Lessons: Endocrine Management of Advanced Breast Cancer
Robert, N. J., & Denduluri, N. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.05.014 · Cited by 11
Chi, S., Fan, W. Q., Li, Y., Yu, L., Ma, C., Fang, Y., Yang, B., Chen, Y., & Ding, J. N. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102212 · Cited by 11
New Directions for Drug-Resistant Breast Cancer: The CDK4/6 Inhibitors
Nichols, M. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.86 · Cited by 9
Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
Echavarría, I., Jerez, Y., Martín, M., & López‐Tarruella, S. (2017) · Breast Care · doi:10.1159/000481656 · Cited by 11
Masuda, N., Mukai, H., Inoue, K., Rai, Y., Ohno, S., Ohtani, S., Shimizu, C., Hashigaki, S., Muramatsu, Y., Umeyama, Y., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01162-4 · Cited by 9
Delbart, D. I., Giri, G. F., Cammarata, A., Pan, M. D., Bareño, L. A. A., Amigo, N. L., Bechis, A., Suárez, A. G., Spanevello, R. A., Villaverde, M. S., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01167-6 · Cited by 9
Palbociclib: A breakthrough in breast carcinoma in women
Gupta, A. K., Sharma, S., Dahiya, N., & Brashier, D. B. S. (2016) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2015.11.002 · Cited by 9
Hilton, J. F., Arnaout, A., & Clemons, M. J. (2013) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000026 · Cited by 9
Expression of regulatory factor X1 can predict the prognosis of breast cancer
Shibata, M., Kanda, M., Shimizu, D., Tanaka, H., Umeda, S., Hayashi, M., Inaishi, T., Miyajima, N., Adachi, Y., Takano, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6005 · Cited by 9
Thomas, N. A., Abraham, R. G., Dedi, B., & Krucher, N. A. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4658 · Cited by 11
Al-Zubaidi, Y., Pazderka, C., Koolaji, N., Rahman, M. K., Choucair, H., Umashankar, B., Bourget, K., Chen, Y., Rawling, T., & Murray, M. T. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.12.015 · Cited by 9
Song, Y., He, L., Wang, Y., Wu, Q., & Huang, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7589 · Cited by 11
Alsaleh, K. A., Zahwahry, H. A., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel‐Razeq, H., et al. (2021) · JCO Global Oncology · doi:10.1200/go.20.00575 · Cited by 9
Schreier, A., Munoz-Arcos, L. S., Soto, A. A., Sparano, J. A., & Anampa, J. D. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06574-8 · Cited by 11
Mitchell, D. C., Menon, A., & Garner, A. L. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.03.012 · Cited by 12
CDK4/6 inhibitors in breast cancer – fromin vitromodels to clinical trials
Saleh, L., Wilson, C., & Holen, I. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1684559 · Cited by 11
Opportunities for improving cancer treatment using systems biology
Griffiths, J. I., Cohen, A. L., Jones, V., Salgia, R., Chang, J. T., & Bild, A. H. (2019) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2019.10.018 · Cited by 10
Feng, C., Cheng, Z., Xu, Z., Tian, Y., Tian, H., Liu, F., Luo, D., & Wang, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.968872 · Cited by 8
Wu, J., Wang, J., O’Connor, T. N., Tzetzo, S. L., Gurova, K. V., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0369 · Cited by 8
Hao, S., Hou, L., Wang, J., Yan, J.-H., Niu, Y.-F., Cai, Z.-H., Li, F., & Meng, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116971 · Cited by 8
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A. W., Layman, R. M., & Tripathy, D. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70055 · Cited by 23
Ferguson, D. C., Long, D. J., Smith, M. C., Craig-Owens, L. D., Means, J. A., Fadare, O., & Desouki, M. M. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0163-1 · Cited by 8
New agents for the management of resistant metastatic breast cancer
Anampa, J., & Sparano, J. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409206 · Cited by 12
Kim, S., Kim, M. H., Park, S., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Park, B., Kim, S. I., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1543 · Cited by 10
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-6066 · Cited by 8
Liao, G., Wang, Z., Zhang, N., & Dong, P. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1399 · Cited by 8
Shamieh, S. E., Saleh, F., Assaad, S., & Farhat, F. S. (2019) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0027 · Cited by 9
Reddy, S., Barkhane, Z., Elmadi, J., Kumar, L. S., Pugalenthi, L. S., & Ahmad, M. (2022) · Cureus · doi:10.7759/cureus.23901 · Cited by 10
Ahmad, A., Wang, Z. P., Ali, R., Bitar, B., Farah, T., Main, Y., Bao, B., Ali, S. S., Kong, D., Li, Y., et al. (2012) · InTech eBooks · doi:10.5772/24272 · Cited by 11
Hur, S., Kim, J. H., Yun, J., Ju, Y. W., Han, J. M., Heo, W., Kim, K., Jeong, K., Lee, H., Han, W., et al. (2020) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e20 · Cited by 10
Molecular Mechanisms of Endocrine Resistance
Fu, X., Angelis, C. D., Veeraraghavan, J., Osborne, C. K., & Schiff, R. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-99350-8_11 · Cited by 9
Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells
Jin, G., Wang, K., Liu, Y., Liu, X., Zhang, X., & Zhang, H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200213102849 · Cited by 9
Djakbarova, U., Madraki, Y., Chan, E. T., Wu, T., Atreaga-Muniz, V., Akatay, A. A., & Kural, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.07.579324 · Cited by 9
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Hosseinzadeh, E., Firoozpour, L., & Amanlou, M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108514 · Cited by 7
A Multi-Split-and-Mix Platform for a Variety of Targeted Protein Degradation
Wang, Y., Luo, Q., Xing, Y., Wang, R. Y., Yang, F., Cao, W., Li, Z., & Yin, F. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00444 · Cited by 7
Malorni, L., Tyekucheva, S., Gombos, A., Hasler-Strub, U., Zamagni, C., Chakiba, C., Colleoni, M. A., Mueller, A., Minisini, A. M., Taylor, D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.016 · Cited by 11
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Knudsen, E. S., Witkiewicz, A. K., & Kabraji, S. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01431-5 · Cited by 9
Ribociclib for the Treatment of Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
López‐Tarruella, S., Jerez, Y., Márquez‐Rodas, I., Echavarría, I., & Martín, M. (2017) · Future Oncology · doi:10.2217/fon-2017-0183 · Cited by 7
First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Cobec, I. M., Moleriu, L. C., Moatar, A. E., & Rempen, A. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9954 · Cited by 8
Prediction of allosteric druggable pockets of cyclin-dependent kinases
Ning, S., Wang, H., Zeng, C., & Zhao, Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac290 · Cited by 8
Wu, X., Jin, N., Gao, H., Yan, M., Chen, Q., Sun, T., Hao, C., Zhao, Y., Han, X., Pan, Y., et al. (2023) · Cancers · doi:10.3390/cancers15174360 · Cited by 8
Attia, M. F., Ogunnaike, E. A., Pitz, M. E., Elbaz, N. M., Panda, D. K., Alexander-Bryant, A. A., Saha, S., Whitehead, D. C., & Kabanov, A. V. (2023) · Biomaterials Science · doi:10.1039/d3bm01888a · Cited by 7
Ralser, D. J., Kiver, V. I. I., Solomayer, E., Neeb, C., Blohmer, J., Abramian, A. V., Maass, N., Schütz, F., Kolberg‐Liedtke, C., Müller, C., et al. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07761-2 · Cited by 7
Postmenopausal hormone receptor-positive advanced breast cancer.
Connolly, R. M., & Stearns, V. (2013) · PubMed · Cited by 7
Shi, G., Yoshida, Y., Yuki, K., Nishimura, T., Kawata, Y., Kawashima, M., Iwaisako, K., Yoshikawa, K., Kurebayashi, J., Toi, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8620 · Cited by 10
Abdel‐Razeq, H. (2018) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2018.04.002 · Cited by 8
Hamidi, H., & Kretzler, M. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000446 · Cited by 7
Wang, X., Lin, P., Li, Y., Chen, G., Yang, H., He, Y., Li, Q., & Liu, R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7817 · Cited by 8
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
Yao, L., Wang, M., Wang, M., Yu, X., Guo, J., Sun, T. C., Li, X., & Xu, Y. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i15.1937 · Cited by 9
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
Ditsch, N., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1464-1221 · Cited by 8
FDA approved six-membered ring fused pyrimidine-based derivatives
Arora, S., & Kumar, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18616-5.00011-9 · Cited by 8
Liang, Y., Liu, X., Yun, Z., Li, K., & Li, H. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220501 · Cited by 10
Molecular Changes Associated With Tumor Initiation and Progression of Soft Tissue Sarcomas
Halcrow, P. W., Dancer, M., Panteah, M., Walden, C. D., & Ohm, J. E. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.10.001 · Cited by 8
Luminal A breast cancer resistance mechanisms and emerging treatments
Anderson, D. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00010-3 · Cited by 16
Masuda, N., Kosaka, N., Iwata, H., & Toi, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02013-8 · Cited by 7
Li, X., Beeghly-Fadiel, A. C., Bhavnani, S. K., Tavana, H., Rubinstein, S. M., Gyawali, B., Riaz, I. B., Fernandes, H., & Warner, J. L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.4361 · Cited by 7
Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents
Terret, C., & Russo, C. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0519-5 · Cited by 8
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
Goel, S., & Tolaney, S. M. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30627-8 · Cited by 7
He, Y., Yang, K., Liu, J., Shi, D., Zhang, Z., Yang, J., Chen, M., & Zhao, P. (2023) · Disease Markers · doi:10.1155/2023/8371623 · Cited by 8
Lee, Y., Lee, D., Seo, I., Chae, H., Sim, S. H., Lee, K. S., & Gwak, H. S. (2023) · Cancers · doi:10.3390/cancers15102810 · Cited by 6
Tang, T., Liu, N., Wang, L., Zuo, K., & Zhu, X. (2024) · ChemBioChem · doi:10.1002/cbic.202400426 · Cited by 7
Gullick, G., Owen, C. N., Watkins, W. J., Cook, S., Helbrow, J., Reed, H., Squires, R., PARK, S. W., Weir, E., Aquilina, F., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100064 · Cited by 12
Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations
Furth, P. A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06736.x · Cited by 6
Brufsky, A. (2014) · The Breast Journal · doi:10.1111/tbj.12278 · Cited by 6
Promise of Cyclin-Dependent Kinases 4/6 as Therapeutic Targets in Breast Cancer
Yang, C. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000191 · Cited by 5
Héquet, D., Mzoughi, S., Rouzier, R., & Guccione, E. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.01.005 · Cited by 6
Cruz, M. R. D. S., Reinert, T., & Cristofanilli, M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.965 · Cited by 7
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.